MARKET

PEN

PEN

Penumbra
NYSE

Real-time Quotes | Nasdaq Last Sale

250.16
-9.82
-3.78%
Closed 16:00 11/26 EST
OPEN
256.91
PREV CLOSE
259.98
HIGH
260.14
LOW
250.00
VOLUME
92.86K
TURNOVER
--
52 WEEK HIGH
320.00
52 WEEK LOW
163.49
MARKET CAP
9.35B
P/E (TTM)
279.01
1D
5D
1M
3M
1Y
5Y
PFM Health Sciences, LP Buys Erasca Inc, Caribou Biosciences Inc, Cytokinetics Inc, Sells , ...
GuruFocus News · 11/16 20:38
CEO Of Penumbra Trades $3.9M In Company Stock
Adam Elsesser, CEO at Penumbra (NYSE:PEN), made a large buy and sell of company shares on November 11, according to a new SEC filing.
Benzinga · 11/16 15:22
Notable Penumbra Insider Trades $750K In Company Stock
Johanna Roberts, Insider at Penumbra (NYSE:PEN), made a large buy and sell of company shares on November 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Johanna Roberts exercised...
Benzinga · 11/11 16:23
Can Mixed Fundamentals Have A Negative Impact on Penumbra, Inc. (NYSE:PEN) Current Share Price Momentum?
Penumbra's (NYSE:PEN) stock is up by a considerable 6.6% over the past month. However, we decided to pay attention to...
Simply Wall St. · 11/11 14:39
Penumbra Inc (PEN) EVP, Gen. Counsel & Secretary Johanna Roberts Sold $698,025 of Shares
GuruFocus News · 11/11 13:15
SoldierStrong and Penumbra to Support Veterans With Novel Immersive Healthcare Technology
Penumbra to donate REAL® Immersive Systems to SoldierStrong to support the physical rehabilitation of the men and women of the U.S. Armed Forces and veterans with virtual realitySoldierStrong has donated $4.2 million to-date in the latest medical technolog...
GlobeNewswire · 11/10 14:08
Penumbra's Thrombectomy System Shows Safety, Clinical Benefit
Benzinga · 11/05 17:36
BRIEF-New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with Penumbra’s Indigo System CAT RX Catheter in High-Risk Patients with Acute Coronary Syndrome
reuters.com · 11/05 15:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PEN. Analyze the recent business situations of Penumbra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PEN stock price target is 329.83 with a high estimate of 350.00 and a low estimate of 308.00.
High350.00
Average329.83
Low308.00
Current 250.16
EPS
Actual
Estimate
0.050.170.290.41
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 373
Institutional Holdings: 32.45M
% Owned: 86.85%
Shares Outstanding: 37.36M
TypeInstitutionsShares
Increased
94
961.47K
New
30
550.14K
Decreased
102
951.35K
Sold Out
32
562.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.57%
Healthcare Equipment & Supplies
-0.85%
Key Executives
Chairman/Chief Executive Officer/Director
Adam Elsesser
Chief Financial Officer
Maggie Yuen
Corporate Executive
James Pray
Executive Vice President/General Counsel/Secretary
Johanna Roberts
Executive Vice President
Lynn Rothman
Chief Accounting Officer
Lambert Shiu
Other/Director
Arani Bose
Lead Director/Independent Director
Janet Leeds
Independent Director
Harpreet Grewal
Independent Director
Don Kassing
Independent Director
Bridget O'rourke
Independent Director
Surbhi Sarna
Independent Director
Thomas Wilder
No Data
About PEN
Penumbra, Inc. is a global healthcare company. The Company is engaged in the design, development, manufacturing, and marketing of medical devices. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization and access technologies. The Company's neuro products include Thrombectomy, Embolization, Neurovascular access, Neurosurgical Tools, and Virtual Reality Platform. Its Vascular products include Thrombectomy and Embolization. The principal specialist physicians and healthcare providers in its two target end markets include Neuro: Interventional neuroradiologists, neurosurgeons, interventional neurologists, occupational therapists, physical therapists, and physiatrists; Vascular: Interventional radiologists, vascular surgeons, and interventional cardiologists. The common vascular and neurovascular diseases the Company focuses on are Ischemic Stroke, Brain Aneurysm, Hemorrhagic Stroke, Venous Thromboembolism, and Acute Coronary Syndrome.

Webull offers kinds of Penumbra Inc stock information, including NYSE:PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.